COVID-19

In his weekly clinical update, Dr. Griffin discusses the fourth US case of H5N1 human infection and reminds the audience of the definition of “pasteurization” before reviewing the recent statistics on SARS-CoV-2 infection, where to find PEMGARDA, the effectiveness of molnupiravir and dexamethasone, convalescent plasma, what to do when healthcare workers succumb to SARS-CoV-2 infection, how an EEG can be used to look for signatures of cognitive decline after SARS-CoV-2 infection and what we observed 2 years following SARS-CoV-2 infection for tissue-resident T cell and viral RNA persistence.

In his weekly clinical update, Dr. Griffin discusses RSV vaccination recommendations and revisions to guidelines before reviewing the recent statistics on SARS-CoV-2 infection, data suggesting that individuals with high HLA-DQA2 expression (MHC class II) are…

In his weekly clinical update, Dr. Griffin reviews the recent statistics on SARS-CoV-2 infection, before discussing methods for sterilizing filtering facepieces, an update to the fall COVID boosters, the emergency use application of a pre-exposure prophylactic and where to find it and drug interaction database, convalescent plasma, the effectiveness of the monoclonal antibody sotrovimab against Omicorn variants, what to do when healthcare workers succumb to SARS-CoV-2 infection, the need for better nursing resources, how survivors of COVID-19-associated ARDS exhibited sustained elevation in endothelial dysfunction biomarkers, correlating with the severity of impaired gas exchange, reactivation of latent CMV as a consequence of a SARS-CoV-2 infection, identification of variables that might impact or predict a person’s time to recovery from an acute SARS-CoV-2 infection and if COVID-19 patients really have olfactory dysfunction more often than normally smelling individuals.

In his weekly clinical update, Dr. Griffin discusses expanded use of the RSV vaccine by GSK, how the youngest member of the MicrobeTV family was hospitalized with RSV, why we are seeing more RSV infections than before the pandemic and how administration of monoclonal antibody therapy does not prevent infection but disease, before reviewing the weekly US COVID update, how SARS-CoV-2 affects neurodevelopment of the fetus and probability of preeclampsia, if giving Paxlovid prevents long COVID, and FDA recommends switching from the XBB.1.5 variant to JN.1 for fall COVID-19 vaccine formulations.

In his weekly clinical update, Dr. Griffin reports the third case of influenza H5N1 infection in a human, this time with respiratory symptoms, an H5 avian influenza virus wastewater dashboard, FDA approves Moderna’s mRNA vaccine for respiratory syncytial virus, vaccine advisors to FDA recommend switching from the XBB.1.5 variant to JN.1 for fall COVID-19 vaccine formulations, weekly US COVID update, a controlled human exhaled breath aerosol experimental study on the relative efficacy of masks and respirators as source control for viral aerosol shedding from people infected with SARS-CoV-2, systematic review of early use of oral antiviral drugs and the risk of post COVID-19 syndrome, long-COVID autonomic syndrome in working age and work ability impairment, Centers for Disease Control and Prevention estimates that 5.3% of Americans currently have long COVID, and the National Academies of Sciences, Engineering, and Medicine presented a report with  a number of conclusions about long-COVID diagnosis, symptoms, and impact on daily function.